TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer
AbstractAn analytical TD-GC-MS method was developed and used for the assessment of volatile organic compounds (VOCs) released from the blood plasma of dogs with/without cancer. VOCs released from 40 samples of diseased blood and 10 control samples were compared in order to examine the difference between both sample groups that were showing qualitatively similar results independent from the disease’s presence. However, mild disturbances in the spectra of dogs with cancer in comparison with the control group were observed, and six peaks (tentatively identified by comparison with mass spectral library as hexanal, octanal, toluene, 2-butanone, 1-octen-3-ol and pyrrole) revealed statistically significant differences between both sample groups, thereby suggesting that these compounds are potential biomarkers that can be used for cancer diagnosis based on the blood plasma TD-GC-MS analysis. Statistical comparison with the application of principal component analysis (PCA) provided accurate discrimination between the cancer and control groups, thus demonstrating stronger biochemical perturbations in blood plasma when cancer is present.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Selyanchyn, R.; Nozoe, T.; Matsui, H.; Kadosawa, T.; Lee, S.-W. TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer. Diagnostics 2013, 3, 68-83.
Selyanchyn R, Nozoe T, Matsui H, Kadosawa T, Lee S-W. TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer. Diagnostics. 2013; 3(1):68-83.Chicago/Turabian Style
Selyanchyn, Roman; Nozoe, Takuma; Matsui, Hidetaka; Kadosawa, Tsuyoshi; Lee, Seung-Woo. 2013. "TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer." Diagnostics 3, no. 1: 68-83.